Skip to main content
SpringerLink
Log in

Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON)

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

The toxicity of the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) administered as a 24 hour infusion has been evaluated. Studies of the clinical pharmacology of the drug have also been performed in 3 patients. The limiting toxicity of the drug was acute nausea, vomiting and diarrhea that was dose dependent in its severity and duration. The maximum tolerated dose was 600 mg/m2 over 24 hours. The other major toxicity was thrombocytopenia that was maximal 7–10 days after the completion of the infusion. The drug does not exhibit renal, hepatic or central nervous system toxicity. DON achieves steady state levels during these infusions and is eliminated by first order kinetics when the infusion is completed (t1/2α = 1.81 h). The principal route of excretion is renal. A starting dose of 400 mg/m2 would be acceptable for Phase II studies of this drug administered on this schedule.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Levintow L: The glutamyltransferase activity of normal and neoplastic tissues. JNCI 15:347–352, 1954

    Google Scholar 

  2. Ghosh S, Blumenthal HG, Davidson E et al.: Glucosamine metabolism. V. Enzymatic synthesis of glucosamine-6-phosphate. J Biol Chem 235:1265–1273, 1960

    Google Scholar 

  3. Moore EC, Lepage GA: In vivo sensitivity of normal and neoplastic mouse tissues to azaserine. Cancer Res 17:804–808, 1957

    Google Scholar 

  4. Edidinoff ML, Knoll JE, Marano B et al.: Effect of DON (6-diazo-5-oxo-L-norleucine) on incorporation of precursors into nucleic acid pyrimidines. Cancer Res 18:105–109, 1985

    Google Scholar 

  5. Barclay RK, Phillips MA: Effects of 6-diazo-5-oxo-L-norleucine on the incorporation of precursors into nucleic acids. Cancer Res. 22:809–814, 1962

    Google Scholar 

  6. Tiemeier DC, Milman G: Chinese hamster liver glutamine synthetase. J Biol Chem 247:2272–2277, 1972

    Google Scholar 

  7. Overjera A, Houchens DP, Catane R et al.: Efficacy of 6-diazo-5-oxo-L-norleucine against experimental tumors in conventional and nude mice. Cancer Res 39:3220–3224, 1979

    Google Scholar 

  8. Magill GB, Myers WPL, Reilly HC et al.: Pharmacological and initial therapeutic observations on 6-diazo-5- oxo-L-norleucine (DON) in human neoplastic disease. Cancer 10:1138–1150, 1957

    Google Scholar 

  9. Veterans Administration Cancer Chemotherapy Study Group. A clinical study of the comparative effects of nitrogen mustard and DON in patients with bronchogenic carcinoma, Hodgkin's disease, lymphosarcoma, and melanoma, JNCI 22:433–439, 1959

    Google Scholar 

  10. Lim C: Management of choriocarcinoma and related tumors of uterus and testis. Med Clin North Am 45:661–676, 1961

    Google Scholar 

  11. Pittillo RF, Woolley C, Brockman RW et al.: Azotomycin (NSC-56654): biologic fate in mice and man. Cancer Chemother Rep 55:47–52, 1971

    Google Scholar 

  12. Weiss AF, Ramirez G, Grace T et al.: Phase II study of azotomycin (NSC-56654). Cancer Chemother Rep 52:611–614, 1968

    Google Scholar 

  13. Sklaroff RB, Casper ES, Magil GB, Young CW: Phase I study of 6-diazo-5-oxo-L-norleucine (DON) Cancer Treat Rep 64:1247–1251, 1980

    Google Scholar 

  14. Holford NHG: DRUGFUN, in Prophet Public Procedures Notebook (HM Perry, ed) Bolt Beranek and Newman Inc., Cambridge Ma. January, 1982

    Google Scholar 

  15. Knott CD: MLAB, A Mathematical Modelling Tool. Computer Programs Biomed 10:271–280, 1979

    Google Scholar 

  16. Cooney DA, Jayaram HN, Milman HA, Homan ER, Pittillo R, Geran RI, Ryan J, Rosenbluth RJ: DON, CONV and DONV, III. Pharmacologic and Toxicologic Studies. Biochem Pharmacol 25:1859–1870, 1976

    Google Scholar 

  17. Colowick SP, Womack FC: Binding of diffusible molecules by macromolecules: rapid measurement by rate of dialysis. J Biol Chem 244:774–777, 1969

    Google Scholar 

  18. Rubin J, Sorensen S, Schutt AJ, Van Hazel GA, O'Connell MJ, Moertel CG: A phase II study of 6-diazo-5-oxo-L-norleucine (DON, NSC 7365) in advanced large bowel carcinoma. Am J Clin Oncol 6:325–326, 1983

    Google Scholar 

  19. Luc VT, Rosenoff S, Woolley PV: Interaction of mAMSA with serum protein. (Abstract) Proc Am Assoc Cancer Res 22:176, 1981

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Medical Oncology and V. T. Lombardi Cancer Research Center, Georgetown University Hospital, 20007, Washington, D.C., USA

    Aquilur Rahman Ph.D., Frederick P. Smith, Phuong-Van T. Luc & Paul V. Woolley

Authors
  1. Aquilur Rahman Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederick P. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Phuong-Van T. Luc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul V. Woolley
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rahman, A., Smith, F.P., Luc, PV.T. et al. Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON). Invest New Drugs 3, 369–374 (1985). https://doi.org/10.1007/BF00170760

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00170760

Keywords

Search

Navigation